Business Insider

Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer

SHANGHAI, March 19, 2020 /PRNewswire/ -- Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma"), a leading biopharmaceutical company in China, announced that the National Medical Products ...
ascopubs.org

Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation.

Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Business Wire

Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC) SHANGHAI--(BUSINESS WIRE)--Hansoh Pharmaceutical Group Company ...
FierceBiotech

Borisy's EQRx bags rights to EGFR inhibitor to drive discount me-too plan

Alexis Borisy’s EQRx has secured the ex-China rights to Hansoh Pharmaceutical’s almonertinib. The deal sets EQRx up to work the EGFR inhibitor into its plan to market me-too drugs at radical discounts ...
Reuters

Hansoh Pharmaceutical Group Tablets Developed By Unit Granted Drug Registration Approval

* ALMONERTINIB MESYLATE TABLETS DEVELOPED BY UNIT GRANTED DRUG REGISTRATION APPROVAL BY NMPA OF PRC Source text for Eikon: Further company coverage: ...